266 related articles for article (PubMed ID: 17922629)
1. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.
Lewiecki EM
Expert Opin Investig Drugs; 2007 Oct; 16(10):1663-72. PubMed ID: 17922629
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis.
Kung AW; Chu EY; Xu L
Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558
[TBL] [Abstract][Full Text] [Related]
3. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
Sharifi M; Lewiecki EM
Expert Rev Clin Pharmacol; 2014 May; 7(3):281-91. PubMed ID: 24580081
[TBL] [Abstract][Full Text] [Related]
4. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.
Palacios S; Mejía Ríos A
Drugs Today (Barc); 2015 Feb; 51(2):107-16. PubMed ID: 25756066
[TBL] [Abstract][Full Text] [Related]
5. Tissue selective estrogen complex (TSEC): a review.
Pickar JH; Boucher M; Morgenstern D
Menopause; 2018 Sep; 25(9):1033-1045. PubMed ID: 29533367
[TBL] [Abstract][Full Text] [Related]
6. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
Komm BS; Mirkin S; Jenkins SN
Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
[TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
Pinkerton JV; Stovall DW
Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
[TBL] [Abstract][Full Text] [Related]
8. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.
Rossini M; Lello S; Sblendorio I; Viapiana O; Fracassi E; Adami S; Gatti D
Drug Des Devel Ther; 2013; 7():601-10. PubMed ID: 23901263
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.
de Villiers TJ
Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423
[TBL] [Abstract][Full Text] [Related]
10. Tissue-selective estrogen complexes for postmenopausal women.
Mirkin S; Komm BS
Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
13. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
Stovall DW; Tanner-Kurtz K; Pinkerton JV
Drugs; 2011 Sep; 71(13):1649-57. PubMed ID: 21902289
[TBL] [Abstract][Full Text] [Related]
14. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.
Kharode Y; Bodine PV; Miller CP; Lyttle CR; Komm BS
Endocrinology; 2008 Dec; 149(12):6084-91. PubMed ID: 18703623
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
16. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
Palacios S; Currie H; Mikkola TS; Dragon E
Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
[TBL] [Abstract][Full Text] [Related]
17. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
Tella SH; Gallagher JC
Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.
Gatti D; Rossini M; Sblendorio I; Lello S
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):883-92. PubMed ID: 23621618
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
